15 December 2022 · Practical guidance to ensure opportunities to learn from local intelligence, including patient harm are translated into shared local and national learning
11 June 2024 · A systematic approach should be taken to responding to reports of possible malicious tampering, securing the evidence, and seeking specialist advice and support
16 March 2021 · Medicines with RMM may not be suitable for inclusion within Patient Group Directions (PGDs). If used, the RMM must be stated within the PGD.
25 January 2023 · Individuals receiving healthcare should be supported to continue to self-administer existing/new medications unless there are reasons why they are unable to
31 July 2018 · Intended audience: This document is intended as a reference and source of information to the following audiences: Nursing staff who handle cytotoxic chemotherapy (Oncology /…
12 July 2023 · Infusion by gravity is not the preferred method of administration, but may be necessary in some circumstances. Ensure a risk assessment is undertaken.
6 March 2024 · Timely use of rasburicase for treatment of Tumour Lysis Syndrome is essential. Mitigation strategies can minimise harm associated with delayed therapy.
15 September 2023 · Medication Safety Across the System (MSATS) provides resources and networking to inspire and equip individuals in promoting the safe use of medicines.